Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Oncoinvent Solutions AS
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06504147CT.gov A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery | — | Recruiting | — | — | — |
NCT03732768CT.gov Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peritoneal Carcinomatosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Radspherin (this asset) | Oncoinvent Solutions AS | P2 | B · 58 |
| Fluorouracilum | Ciusss de L'Est de l'Île de Montréal | P3 | BB |
| Oxaliplatin | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | P3 | BB |
| Muamycin | H. Lee Moffitt Cancer Center and Research Institute | P4 | BB |
| Irinotecan | Catharina Ziekenhuis Eindhoven | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | BB |
| Capecitabine | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | P2/3 | BB |
| Indocyanine Green | Jules Bordet Institute | P2 | B |
| Sodium Thiosulfate | National Cancer Institute (NCI) | P2 | B |
+33 more in the Peritoneal Carcinomatosis cohort
Other indications for Radspherin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peritoneal Carcinoma | — | P1/2 | CCC · 52 |
| Ovarian Cancer | — | P2 | CCC · 50 |
| Colorectal Carcinoma | — | P1/2 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FluorouracilumCiusss de L'Est de l'Île de MontréalBB
- OxaliplatinDaping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityBB
- MuamycinH. Lee Moffitt Cancer Center and Research InstituteBB
- IrinotecanCatharina Ziekenhuis EindhovenBB
- Cis-Diamminedichloroplatinum IiNational Cancer Institute (NCI)BB
Citation
Floatz Terminal. Radspherin in Peritoneal Carcinomatosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/radspherin-peritoneal-carcinomatosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →